Recommendations for Mutational Analysis of Various Solid Tumors

Ezra Cohen, MD, FRCPSC, FASCO; Mary Jo Fidler, MD; Arturo Loaiza-Bonilla, MD, MSEd, FACP

Video Categories: NTRK Gene Fusions

Dr Ezra Cohen of UC San Diego, La Jolla, CA; Dr Mary Fidler Rush of University Medical Center, Chicago, IL; and Dr Arturo Loaiza-Bonilla of the Comprehensive Care and Research Center, Philadelphia, PA, explain which targetable mutation should be screened for various solid tumors.

October 7, 2016

Tailoring Treatment Regimens for Patients with HR+/HER2-Negative Metastatic Breast Cancer

Dr Sunil Verma identifies how he makes treatment decisions for his patients, noting that he tends to use endocrine treatments instead of chemotherapy.

October 23, 2018

Creating a Paradigm for Biomarker Testing

Drs. Goeffrey Oxnard and Lauren Ritterhouse consider the advantages and disadvantages of liquid biopsies as an early screening tool for biomarker testing, and how to integrate various approaches into a biomarker testing paradigm.